Stocks in play: Neovasc Inc.
Announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval application from the U.S. Food and Drug Administration for its Neovasc Reducer™ medical device for the treatment of refractory angina. Neovasc Inc. shares T.NVCN are trading up $0.28 at $4.33.
Read: Why 2020 Should be a Big Year for Psilocybin "Magic" Mushrooms